Analytic sensitivity and specificity of enzyme immunoassay results in testing for human immunodeficiency virus type 1 antibody.
In 1986, a performance evaluation program at the Centers for Disease Control was implemented to assess the quality of performance of laboratories testing for human immunodeficiency virus type 1 antibody and to identify problems that occur during the testing process. Laboratories participating in the Centers for Disease Control Model Performance Evaluation Program for human immunodeficiency virus type 1 antibody testing furnished enzyme immunoassay results after they tested performance evaluation panels that were sent to them in August and November 1989. The panels consisted of 10 individual samples containing antibody-negative and antibody-positive samples, some of which were duplicates. Not all laboratories received the same panel of samples. Low false-negative and false-positive rates, as well as high intrashipment and intershipment reproducibility, indicate that most laboratories did not experience difficulty in testing performance evaluation samples sent to them in August and November 1989.
Cross
G D
GD
Laboratory Practice Assessment Branch, Centers for Disease Control, US Department of Health and Human Services, Atlanta, Ga 30333.
Schalla
W O
WO
Hancock
J S
JS
Hearn
T L
TL
Blumer
S O
SO
Taylor
R N
RN
Valdiserri
R O
RO
D005069:Evaluation Studies as Topic; D015483:HIV Antibodies / Q000032:analysis*; D015658:HIV Infections / Q000175:diagnosis; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000592:standards*; D007753:Laboratories / Q000592:standards*; D011785:Quality Assurance, Health Care; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires
D015483:HIV Antibodies; D011933:Reagent Kits, Diagnostic